Presenting at AHS 2022, researchers assessed the efficacy of a 1-year treatment period with ubrogepant 50 or 100 mg in patients with migraine attacks with mild and moderate or severe pain.
Patients with treatment-resistant major depressive disorder or bipolar disorder without psychotic symptoms received intravenous infusions of 0.5 mg/kg ketamine 3 times per week for 2 weeks.
Presenting at the 2022 AAN Annual Meeting, researchers assessed the safety and efficacy of monthly erenumab among adult patients with chronic migraine with Asian ancestry.
Long-term chimeric antigen receptor (CAR) T cell signaling and persistence has been demonstrated at more than 10 years after infusion in 2 chronic lymphocytic leukemia (CLL) patients.
Adults with chronic pain use a variety of pain management strategies, including opioids, but the majority use nonopioid management techniques.
A healthier lifestyle is associated with lower rheumatoid arthritis (RA) risk.
Unintentional opioid deaths from July 2017 to June 2020, the pre and post Covid-19 era, are described by key decedent and death scene characteristics.
Researchers conducted a study to assess the effect of galcanezumab on the total pain burden of patients with episodic cluster headache.
Study authors conducted a meta-analysis of randomized controlled trials to study the effectiveness of psychotropic medications in children and adolescents with chronic pain.
The objective of this systematic review was to study the effects of lidocaine on postoperative pain scores and recovery after cardiac surgery.
